Turkish Journal of Hematology Volume: 37 Issue: 1 / 2020

Matsumura A, et al: ST2 for Transplant-related Complications
Turk J Hematol 2020;37:20-29
4. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong
CH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D,
Reddy P, Ferrara JL, Paczesny S. ST2 as a marker for risk of therapy-resistant
graft-versus-host disease and death. N Engl J Med 2013;369:529-539.
5. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, Misek
DE, Cooke KR, Kitko CL, Weyand A, Bickley D, Jones D, Whitfield J, Reddy P,
Levine JE, Hanash SM, Ferrara JL. A biomarker panel for acute graft-versushost
disease. Blood 2009;113:273-278.
6. Kennedy GA, Varelias A, Vuckovic S, Le Texier L, Gartlan KH, Zhang P, Thomas
G, Anderson L, Boyle G, Cloonan N, Leach J, Sturgeon E, Avery J, Olver SD,
Lor M, Misra AK, Hutchins C, Morton AJ, Durrant ST, Subramoniapillai
E, Butler JP, Curley CI, MacDonald KP, Tey SK, Hill GR. Addition of
interleukin-6 inhibition with tocilizumab to standard graft-versus-host
disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2
trial. Lancet Oncol 2014;15:1451-1459.
7. Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B, Olsen S,
Choi SW, Wang H, Faca V, Pitteri S, Zhang Q, Chin A, Kitko C, Mineishi S,
Yanik G, Peres E, Hanauer D, Wang Y, Reddy P, Hanash S, Ferrara JL. Elafin
is a biomarker of graft-versus-host disease of the skin. Sci Transl Med
2010;2:13ra12.
8. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, Levine
JE, Choi SW, Huber E, Landfried K, Akashi K, Vander Lugt M, Reddy P, Chin
A, Zhang Q, Hanash S, Paczesny S. Regenerating islet-derived 3-alpha
is a biomarker of gastrointestinal graft-versus-host disease. Blood
2011;118:6702-6708.
9. Harris AC, Ferrara JL, Braun TM, Holler E, Teshima T, Levine JE, Choi SW,
Landfried K, Akashi K, Vander Lugt M, Couriel DR, Reddy P, Paczesny S.
Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood
2012;119:2960-2963.
10. Levine JE, Logan BR, Wu J, Alousi AM, Bolanos-Meade J, Ferrara JL, Ho
VT, Weisdorf DJ, Paczesny S. Acute graft-versus-host disease biomarkers
measured during therapy can predict treatment outcomes: a Blood and
Marrow Transplant Clinical Trials Network study. Blood 2012;119:3854-3860.
11. Hansen JA, Hanash SM, Tabellini L, Baik C, Lawler RL, Grogan BM, Storer B,
Chin A, Johnson M, Wong CH, Zhang Q, Martin PJ, McDonald GB. A novel
soluble form of Tim-3 associated with severe graft-versus-host disease. Biol
Blood Marrow Transplant 2013;19:1323-1330.
12. McDonald GB, Tabellini L, Storer BE, Lawler RL, Martin PJ, Hansen JA. Plasma
biomarkers of acute GVHD and nonrelapse mortality: predictive value of
measurements before GVHD onset and treatment. Blood 2015;126:113-120.
13. Abu Zaid M, Wu J, Wu C, Logan BR, Yu J, Cutler C, Antin JH, Paczesny S,
Choi SW. Plasma biomarkers of risk for death in a multicenter phase 3
trial with uniform transplant characteristics post-allogeneic HCT. Blood
2017;129:162-170.
14. Yu J, Storer BE, Kushekhar K, Abu Zaid M, Zhang Q, Gafken PR, Ogata Y,
Martin PJ, Flowers ME, Hansen JA, Arora M, Cutler C, Jagasia M, Pidala
J, Hamilton BK, Chen GL, Pusic I, Lee SJ, Paczesny S. Biomarker panel for
chronic graft-versus-host disease. J Clin Oncol 2016;34:2583-2590.
15. Rotz SJ, Dandoy CE, Davies SM. ST2 and endothelial injury as a link between
GVHD and microangiopathy. N Engl J Med 2017;376:1189-1190.
16. Akil A, Zhang Q, Mumaw CL, Raiker N, Yu J, Velez de Mendizabal N, Haneline
LS, Robertson KA, Skiles J, Diaz-Ricart M, Carreras E, Renbarger J, Hanash
S, Bies RR, Paczesny S. Biomarkers for diagnosis and prognosis of sinusoidal
obstruction syndrome after hematopoietic cell transplantation. Biol Blood
Marrow Transplant 2015;21:1739-1745.
17. Griesenauer B, Paczesny S. The ST2/IL-33 axis in immune cells during
inflammatory diseases. Front Immunol 2017;8:475.
18. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK,
Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-
33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related
protein ST2 and induces T helper type 2-associated cytokines. Immunity
2005;23:479-490.
19. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to
the future. Immunity 2013;39:1003-1018.
20. Reichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, Liu
Q, Koehn BH, Pfeifer D, Taylor PA, Prinz G, Dierbach H, Stickel N, Beck Y,
Warncke M, Junt T, Schmitt-Graeff A, Nakae S, Follo M, Wertheimer T,
Schwab L, Devlin J, Watkins SC, Duyster J, Ferrara JL, Turnquist HR, Zeiser
R, Blazar BR. The IL-33/ST2 axis augments effector T-cell responses during
acute GVHD. Blood 2015;125:3183-3192.
21. Matta BM, Reichenbach DK, Zhang X, Mathews L, Koehn BH, Dwyer GK, Lott
JM, Uhl FM, Pfeifer D, Feser CJ, Smith MJ, Liu Q, Zeiser R, Blazar BR, Turnquist
HR. Peri-alloHCT IL-33 administration expands recipient T-regulatory cells
that protect mice against acute GVHD. Blood 2016;128:427-439.
22. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin
S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M.
Defining the intensity of conditioning regimens: working definitions. Biol
Blood Marrow Transplant 2009;15:1628-1633.
23. Marks R, Potthoff K, Hahn J, Ihorst G, Bertz H, Spyridonidis A, Holler E, Finke
JM. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan
in allogeneic hematopoietic cell transplantation: particular activity against
advanced hematologic malignancies. Blood 2008;112:415-425.
24. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J,
Thomas ED. 1994 Consensus Conference on Acute GVHD Grading. Bone
Marrow Transplant 1995;15:825-828.
25. Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, Holler E,
Iacobelli M, Kentouche K, Lammle B, Moake JL, Richardson P, Socie G, Zeigler
Z, Niederwieser D, Barbui T, European Group for B, Marrow T, European
L. Diagnostic criteria for hematopoietic stem cell transplant-associated
microangiopathy: results of a consensus process by an International
Working Group. Haematologica 2007;92:95-100.
26. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, Ferrara J, Soiffer
R, Giralt S. Blood and marrow transplant clinical trials network toxicity
committee consensus summary: thrombotic microangiopathy after
hematopoietic stem cell transplantation. Biol Blood Marrow Transplant
2005;11:571-575.
27. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M,
Hardin BJ, Shulman HM, Clift RA. Veno-occlusive disease of the liver and
multiorgan failure after bone marrow transplantation: a cohort study of
355 patients. Ann Intern Med 1993;118:255-267.
28. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG,
Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R. Venoocclusive disease
of the liver following bone marrow transplantation. Transplantation
1987;44:778-783.
29. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for
medical statistics. Bone Marrow Transplant 2013;48:452-458.
30. Kumar S, Tzimas MN, Griswold DE, Young PR. Expression of ST2, an
interleukin-1 receptor homologue, is induced by proinflammatory stimuli.
Biochem Biophys Res Commun 1997;235:474-478.
31. Rossler U, Thomassen E, Hultner L, Baier S, Danescu J, Werenskiold AK.
Secreted and membrane-bound isoforms of T1, an orphan receptor
related to IL-1-binding proteins, are differently expressed in vivo. Dev Biol
1995;168:86-97.
32. Schots R, Kaufman L, Van Riet I, Ben Othman T, De Waele M, Van Camp B,
Demanet C. Proinflammatory cytokines and their role in the development of
major transplant-related complications in the early phase after allogeneic
bone marrow transplantation. Leukemia 2003;17:1150-1156.
28